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ABSTRACT
The sequence asparagine-glycine arginine (NGR), flanked by Cysteine (Cys) 
residues so as to form a disulfide-bridge (CNGRC), has previously been found to 
target and bind specifically to aminopeptidase N (APN), which is highly expressed 
on the surface of tumor cells. The goal of this study was to develop and evaluate 
the potential of fusion proteins carrying the CNGRC sequence linked to the enzyme 
carboxypeptidase G2 (CPG2) for targeted cancer therapy. We refer to this strategy 
as ligand-directed enzyme prodrug therapy (LDEPT).
We constructed two forms of the CNGRC-CPG2 fusions, containing one or two 
copies of the cyclic NGR motif and designated CNGRC-CPG2 (X-CPG2) and CNGRC-
CPG2-CNGRC (X-CPG2-X), respectively. In vitro binding assays of the purified 
constructs showed that both X-CPG2 and X-CPG2-X bound with high affinity to cancer 
cells expressing high levels of APN, compared to their binding to cells expressing low 
levels of APN.
Further in vitro studies of the constructs to assess the therapeutic potential 
of LDEPT were carried out using cells expressing high and low levels of APN. Using 
methotrexate, it was demonstrated that cancer cell survival was significantly higher 
in the presence of the fusion proteins, due to the hydrolysis of this cytotoxic drug by 
CPG2. Conversely, when the prodrug ZD2767P was used, cancer cell killing was higher 
in the presence of the fused CPG2 constructs than in their absence, which is consistent 
with CPG2-mediated release of the cytotoxic drug from the prodrug. Furthermore, 
the doubly-fused CPG2 construct (X-CPG2-X) was significantly more effective than 
the singly-fused construct (X-CPG2).
INTRODUCTION
Metastasis is a key problem preventing cancer 
treatment, and often results in patient death. In the 
advanced stages of cancer, tumor cells break the 
extracellular matrix (ECM) barrier and invade additional 
tissues in a multistep process [1]. Two classes of enzymes 
known to be involved in the ECM degradation are 
aminopeptidase N (APN) and the matrix metalloproteases 
(MMPs). Targeted anti-metastatic agents have been 
developed against MMPs, but to date their efficacy with 
respect to cancer treatment appears to be limited [2].
APN, also known as CD13, is a transmembrane 
receptor with an exopeptidase activity, and is expressed 
in many tissues and cell types [3]. It plays a crucial role 
in metastasis by degrading the ECM thus allowing the 
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escape of tumor cells into the bloodstream [4]. APN also 
promotes angiogenesis and the invasion of neo-endothelial 
cells through the ECM [5].
Several studies have reported that various types of 
cancer cells have abnormally high levels of expression 
of APN, which made it a promising target for cancer 
therapy [6]. Recent studies have developed synthetic APN 
inhibitors and tested their anti-metastasic potency. Some of 
these compounds showed a significant capacity to inhibit 
and/or reduce cancer metastasis in vivo and in vitro [7].
During the late 1990s, a small cyclic peptide 
(asparagine-glycine-arginine) (NGR), discovered via 
phage display libraries, was found to have tumor-homing 
properties and a high binding affinity to APN expressed 
by the neo-angiogenic endothelial cells. Among the 
various isoforms of CD13 expressed by cells, the CNGRC 
peptide binds specifically to a tumor-specific form of 
CD13 [8]. Moreover, deamination of CNGRC produces 
a peptide (isoaspartate-glycine-arginine) that recognizes 
αѴβ3 integrin, which is a highly expressed biomarker of 
angiogenic vessels [9]. Thus, the CNGRC peptide has been 
utilized as a carrier for many cancer-related applications, 
such as cancer cell imaging, and the development of 
novel anti-cancer compounds that could be targeted to 
tumor cells [10]. Early studies established that several 
anti-cancer drugs had increased potency when linked to 
CNGRC, due to their higher localized cytotoxicity. Since 
then, the peptide has been linked or fused with a variety of 
molecules including anti-cancer drugs (e. g. doxorubicin), 
cytokines (interferone γ “IFNγ” and human tumor necrosis 
factor “hTNF”), toxins (A), enzymes (cytosine deaminase 
“CD”, and truncated coagulase) in addition to fusion 
with other therapeutic proteins such as anti-epidermal 
frowth factor receptor “anti-EGFR” and an scFv antibody 
fragment [11–18].
Antibody-directed enzyme prodrug therapy 
(ADEPT) is an appealing method for treating tumors 
with a significantly reduced undesirable side effects. 
This is achieved by directing the enzyme-prodrug 
complex to the tumor site via a tumor-specific antibody. 
Several enzymes have been used in combination with 
a variety of drugs, but only an ADEPT system using 
carboxypeptidase G2 (CPG2) has reached clinical trials 
[19]. CPG2 is an exopeptidase that can be used clinically 
to convert synthetic non-toxic “benzoic mustard prodrugs” 
to cytotoxic moieties. Additionally, CPG2 is used in to 
detoxify patients who have inadvertently been given an 
overdose of methotrexate (MTX) [20, 21]. Methotrexate is 
used in chemotherapy for treatment of various cancers but 
has strong side effects on tissues, especially in the kidney, 
and can lead to renal dysfunction and failure. Accordingly, 
rapid removal of methotrexate is of great importance and 
this can be achieved by administration of CPG2, which 
acts by hydrolyzing the carboxyl terminal glutamate 
moiety of methotrexate to produce the safer products 
glutamic acid and 2,4- diamino-N10-methylpteroic acid 
(DAMPA) [22]. Because of the dual benefits of CPG2 
in cancer treatments, it is considered an enzyme of great 
potential in this area of research.
In the LDEPT strategy, a protein or peptide ligand 
is used to direct the enzyme to the tumor site where the 
prodrug will be converted to cytotoxic drug resulting 
in cancer cell death (Figure 1). In contrast to ADEPT, 
where a relatively large antibody or antibody fragment 
is covalently attached to the enzyme, LDEPT results in 
smaller fusion proteins that are relatively cheap to produce 
and that are less likely to have solubility issues.
In this study, we used two derivatives containing 
a cyclic peptide (CNGRC) that binds with high 
affinity to APN and direct CPG2 to tumor cells. The 
targeting complexes were used in conjunction with 
the prodrug ZD2767P (an alkylating mustard agent), 
which is activated to a potent cytotoxic drug once 
CPG2 hydrolyses and cleaves the glutamate moiety 
[23] (Figure 2). We investigated the specific binding of 
the fusion proteins using cancer cell lines with different 
levels of APN expression. Furthermore, the cytotoxic 
effect of methotrexate and/or the prodrug ZD2767P was 
investigated following treatment with the fusion proteins.
RESULTS
Cloning, overexpression and purification of 
fusion proteins
Two fusion proteins were constructed using 
CNGRC and His-tagged CPG2, as shown in Figure 3A. 
The first construct, designated CNGRC-CPG2 (X-CPG2), 
carried the cyclic NGR motif at the N-terminus while the 
second, designated CNGRC-CPG2-CNGRC (X-CPG2-X), 
had an additional cyclic NGR motif at the C-terminus. 
Sequencing of the plasmids carrying the fusion proteins 
confirmed the predicted structures of the constructs 
(Table 1). The encoded proteins were expressed and 
purified, resulting in a final yield of 3.6 mg, 5 mg and 
6.2 mg of purified WT, single and double fusion proteins, 
respectively, per g cell paste. SDS-PAGE analysis of the 
purified proteins and immunoblotting using an anti-CPG2 
antibody both showed that the doubly-fused protein was 
discernibly larger in size (Figure 3B).
Catalytic activity assay of fusion proteins
E. coli strains expressing each fusion protein were 
grown on agar plates supplemented with folate, as a 
qualitative check that the fusion proteins retained CPG2 
activity. After 24 hours of incubation, all clones produced 
a yellow precipitate, similar to the positive control, and 
developed a clear zone surrounding the area of bacterial 
growth by Day 2 (Figure 4). CPG2 activity associated 
with the fusion proteins was then assessed quantitatively 
by measuring the hydrolysis of methotrexate. The kinetic 
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parameters, maximal initial velocity (Vmax), Michaels-
Menten constant (Km) and turnover number (Kcat) were 
calculated. The results showed a significant increase in the 
Vmax of the enzyme when two copies of the CNGRC motif 
fused to CPG2, relative to the construct with a single copy 
of the motif and non-fused WT CPG2 (Table 2).
CD spectra
Circular dichroism was used to assess the degree of 
conformational change in the fusion proteins relative to 
WT CPG2. The specific shape of the measured far UV 
CD signals for fusion proteins (single and double) relative 
to the WT CPG2 is shown in Figure 5A. The calculated 
secondary structure (Figure 5B) indicates changes in 
the structural composition of CPG2 protein when fused 
with CNGRC (single “X-CPG2” and double fusion 
“X-CPG2-X” proteins). The percentage of alpha helix is 
reduced whereas there is an increase in the percentage of 
beta sheet structure.
Ex-vivo immunogenicity of the fusion proteins 
and their stability in serum
To test the immunogenicity of the generated fusion 
proteins, a T cell proliferation assay was used (Fu et al., 
2014). Unfractionated PBMCs from four healthy donors 
were incubated with the purified endotoxin-free fusion 
proteins (WT, single and double) for 48 hours. According 
to the CCK-8 proliferation assay results, there was no 
significant induction in cell proliferation following 
incubation with fusion proteins, compared with the vehicle 
control groups. In contrast, T-cells were significantly 
induced with LPS (positive) groups and also by the non-
fused CPG2 (Figure 6A). These results suggest that the 
fusion proteins have reduced immunogenicity relative 
to native CPG2. Analysis of the stability of the fusion 
proteins in human serum indicated that they were more 
stable than the non-fused WT. Furthermore, the double 
fusion protein, X-CPG2-X, showed higher stability, 
with more than 70% activity remaining after 12 days of 
incubation in human serum at 37°C (Figure 6B).
Differential binding affinities of fusion proteins 
to cancer cell lines expressing APN
The level of APN expression in different cancer 
cell lines was determined using anti-CD13 antibody 
labeling. The results showed a range of levels of APN 
expression (Figure 7). Some were high (e. g. MDA-MB 
468 and HT1080 cell lines) while others were low (e. 
g. the MDA-MB 231 and A549 cell lines). Two cancer 
cell lines were used to test the binding affinity of the 
fusion proteins, low APN expressing (A549) and high 
APN expressing (HT1080) cell lines. Both the single and 
double fused proteins bound to the high APN expressing 
cells (HT1080), with increasing concentrations. In 
contrast, WT CGP2 did not show significant binding to 
Figure 1: Schematic representation of the Ligand-Directed Enzyme Pro-Drug Therapy (LDEPT) strategy. Tumor cells 
that express cancer specific receptors (such as aminopeptidase N “APN”) are bound via a specific ligand (such as CNGRC) that is attached 
via a linker to a therapeutic enzyme (such as CPG2) that can convert an inactive pro-drug (ZD2767P) to a cytotoxic compound at the site 
of tumor cells.
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HT1080 cells (Figure 8). Interestingly, the double fused 
protein, X-CPG2-X, displayed higher binding affinity 
(Kd 0.4 ± 0.11), compared with the single fused protein (Kd 
0.91 ± 0.15). Neither the fusion proteins nor WT CPG2 
showed significant binding to the low APN expressing cell 
line (A549).
In vitro cytotoxicity of MTX or ZD2767P on 
cancer cell lines treated with the fusion proteins
Previous studies have shown that fusion proteins 
containing CPG2 have potential for the removal of excess 
methotrexate (MTX) during chemotherapy. We therefore 
Figure 2: Structures of the prodrug compound (ZD2676P) used in this study and the cytotoxic compound produced following carbopeptidase 
G2 “CPG2”-mediated hydrolysis and removal of a glutamic acid moiety.
Figure 3: Cloning and production of CNGRC-CPG2 fusion proteins. (A) Schematic representations of the structures of the 
constructed fusion proteins. (B) Left-hand panel: SDS-PAGE analysis of the purified fusion proteins, lanes A, B and C show purified WT, 
single and double fusion proteins respectively. Right-hand panel: western blotting with anti-CPG2 antibody.
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Table 1: Nucleotide and peptide sequences of the CNGRC-CPG2 fusion proteins constructed clones1
Nucleotide sequence CPG2 “WT” CATATGGCCCTGGCCC................. CAAGGGTTGAAAGCTT
X-CPG2 CATATGTGCAACGGTCGTTGTGGTGGTGCCCTGGCCC.............. CAAGGGT 
TGAAAGCTT
X-CPG2-X CATATGTGCAACGGTCGTTGTGGTGGTGCCCTGGCCC............. CAAGGGT 
TGGGTGGTTGCAACGGTCGTTGTAAAGCTT
Peptide sequence CPG2 “WT” H Met A L A Q........ D L G A G K G Stop K L
X-CPG2 H Met C N G R C G G A L A Q.......... D L G A G K G Stop K L
X-CPG2-X H Met C N G R C G G A L A Q............. D L G A G K G G G C N G R C Stop K L
1The linker sequence is indicated in italic while the sequence in bold is for the fused protein part.
Figure 4: Catalytic activity and kinetics of CPG2 and its fusion protein derivatives. (A) E. coli BL21 (DE3) RIL cells 
expressing different CNGRC-CPG2 fusion proteins grown on folate supplemented agar plates. The yellow precipitates indicate CPG2 
proteolytic activity. (+) and (-) are positive and negative controls respectively. P. CPG2: Pseudomonas putida CPG2 was used as a further 
positive control. (B) A graph showing the rate of methotrexate “MTX” hydrolysis by CNGRC-CPG2 proteins. Equal amounts of the 
proteins were used in these assays.
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investigated the degree of MTX cytotoxicity on cells that 
had been treated with the fusion proteins. Cell survival 
was significantly higher in the high APN expressing cells 
that had been pre-treated with either single (X-CPG2) or 
double (X-CPG2-X) fused proteins, compared with the 
positive controls, i. e. cells treated only with the MTX 
(Figure 9). In contrast, there was no significant difference 
in the survival of low APN expressing cells pre-treated 
with the fusion proteins (Figure 9).
We next investigated whether the fusion proteins 
could be used to increase the degree of killing mediated 
by the prodrug ZD2767P. In a previous study, it was 
shown that the prodrug ZD2767P produced a highly 
potent cytotoxic drug with a short in plasma half-life of 
14.5 min [24].
As shown in Figure 9, cells expressing high levels 
if APN (HT1080, MDA-MB486 and HepG2) showed 
significantly lower levels of survival with ZD2767P (about 
50% lower) when treated with the fusion proteins relative 
to the same cells treated with either the non-fused CPG2 
protein or the controls. In contrast, the percentage survival 
of cells expressing low levels of APN (A549, FaDu and 
MDA-MB231) was not significantly affected by the 
prodrug ZD2767P.
DISCUSSION
Conventional cancer treatments such as 
chemotherapy and radiotherapy lack much specificity 
for cancer cells and hence also kill many healthy cells. 
In contrast, antibodies have the potential to deliver with 
accuracy therapeutic enzymes and drugs to tumors, due to 
their specificity for cognate antigens.
One targeted cancer strategy that exploits antibody 
specificity is antibody-directed enzyme prodrug therapy 
(ADEPT) [25, 26], which produces a cytotoxic drug in 
the vicinity of cancer cells using an enzyme (e. g. CPG2) 
linked to cancer-specific antibody and a prodrug. One 
potential advantage of ADEPT is that any cancer cell that 
does not express the required antigen may still be killed 
due to the bystander effect of the released cytotoxic agents. 
The ADEPT system has been successfully used in several 
clinical trials resulting in encouraging tumor responses [27]. 
However, two major problems may decrease its efficacy: (i) 
Table 2: Enzyme kinetics parameters of CPG2 and its CNGRC fusion derivatives
CPG2 X-CPG21 X-CPG2-X1
Kcat “min
-1” 35.64 ± 1.4 29.8 ± 2.06 72.3 ± 1.7
Vmax “µM/min/µg” 75.5 ± 3.5 63.23 ± 5.1 153.3 ± 2.9
Km “µM” 235.6 ± 12.1 171.7 ± 16.5 676 ± 24.07
1X indicates the position (s) of the CNGRC peptide fused to CPG2.
Figure 5: Far UV circular dichroism profiles of CPG2 and its fusion derivatives with the distribution of the β sheets 
and α-helix. The figure shows combined molar ellipticity data for CPG2 (red line), the single fused construct (darker blue line) and the 
double fused construct (cyan line). ‘smooth 0’: CPG2, ‘smooth 1: X-CPG2, and ‘smooth 3′: X-CPG2-X. The obtained spectral data were 
corrected for the baseline buffer.
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the limited choice of tumor markers that can be targeted by 
antibodies and (ii) enzyme immunogenicity, where several 
clinical trials have resulted in high system toxicity due to 
repeated administration of non-human enzymes [28].
To circumvent these issues, the present study 
investigated the use of peptides, fused with CPG2, that 
bind specifically to aminopeptidase N (APN), which is 
often highly expressed on the surfaces of many types of 
Figure 6: (A) Immunogenicity of CPG2 and its fusion protein derivatives. Human PBMCs from four donors were used as described 
in the Materials & Methods section. Cells treated with fusion proteins (X-CPG2 and X-CPG2-X) showed no significant differences in 
immunogenicity compared with the control groups. Student t-test used for the resulting values and relative comparison with the control 
non-treated cells “*P < 0.05, **P < 0.001” (B) Stability of CPG2 and its fusion protein derivatives in human serum at 37°C. The catalytic 
activity of the proteins was assayed every 48 h over a period of 14 days.
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cancer cell. APN is a cancer cell marker known to have a 
major role in cancer cell invasion and angiogenesis [29]. 
It is highly expressed on the cell surface in various solid 
tumors but generally has low levels of expression in normal 
cell types. Different isoforms of APN have been found 
to be expressed by tumor cells, which has allowed the 
development of reagents that bind with high specificity to 
cancer cells. Using phage display libraries, peptides with 
the sequence Asparagine – Glycine – Arginine (NGR) 
sequence, flanked by Cys residues so as to form a disulfide 
bond (CNGRC), were found to bind to a tumor cell-specific 
isoform of APN isoform as well as to tumor blood vessels 
[30]. Accordingly, to pursue our goal of improving tumor-
specific cytotoxicity, we designed two fusion proteins with 
the potential to target this APN isoform. The first fusion 
protein, CNGRC-CPG2 (X-CPG2), consists of the cyclic 
peptide at the N-terminus, a glycine-glycine linker and 
then CPG2 whereas the second has an additional CNGRC 
moiety at the C-terminus (X-CPG2-X) (Figure 3A). Our 
studies indicate that addition of the second copy of the 
CNGRC sequence enhances protein solubility, resulting in 
higher yields of the purified fusion protein (data not shown).
To ensure that the fusion of the peptides did not affect 
CPG2 activity we carried out a series of enzyme kinetic 
studies. The data indicate that addition of a single copy of 
CNGRC to CPG2 had no significant effect on the enzyme’s 
activity. We found, however, that the double fusion construct 
(i. e. with a CNGRC peptide at both the N- and C-termini 
of CPG2) had significantly increased enzyme activity 
comparing to the wild type and the single fused CPG2 
(Figure 4). We speculate that the presence of the additional 
peptide at the C-terminus causes a conformational change 
that leads to an increase in substrate binding.
In keeping with these results, CD spectroscopic 
analysis in the far UV region showed a substantial 
difference in the secondary structure of CPG2 protein 
following double fusion with CNGRC, compared with 
non-fused CPG2. Specifically, there was decrease 
in the percentage of alpha helical structure, which 
was corroborated by the CDNN deconvolution. This 
conformational change is likely to explain the higher Kcat 
value for double fusion protein (X-CPG2-X) (Table 2). The 
higher enzyme activity of the double fused protein suggests 
that it could be useful not only in LDEPT but also in the 
detoxification of methotrexate in overdose cases.
One drawback of ADEPT is the immunogenicity of 
the CPG2 enzyme, which becomes problematical due to 
the need for repeated cycles of treatment. We therefore 
carried an ex-vivo assessment of the immunogenicity of the 
fusion proteins described here. Using a T-cell proliferation 
assay, we found that the fusion proteins appeared to cause 
no significant immunogenic response. However, it remains 
to be seen if the proteins become immunogenic following 
repeated administration to patients.
Encouragingly, we found that most of the enzymatic 
activity of CPG2 was retained following incubation with 
serum for 14 days (Figure 6A). In particular, the double 
fusion protein had ˃70% of its original catalytic activity 
after the incubation for two weeks in human serum 
(Figure 6B). In short, the data obtained so far indicate that 
Figure 7: The levels of APN expression in various cancer cell lines. Left-hand panel: Different cancer cell lines were labeled 
with anti-CD13 antibody and the percentage of CD13 expression was determined as described in the Materials & Methods section. One 
way ANOVA with post hoc Tukey’s test for the resulting values presented with the following symbols indicating statisitical significance 
difference “p < 0.001” in comparison to the stated cell lines: * to MDA-MB231, # to MCF-7, $ to HepG2, & to T47D, % to SW620, b 
to MDA-MB 468, m to LoVo, £ to H661, ¥ to FaDu, § to SCC25 and ∆ to HT1080. Right-hand panels: fluorescence imaging of two low 
(MDA-MB 231 and A549) and two high (HT1080 and MDA-MB 468) APN expressing cell lines. An antibody specific for CD13 was 
detected using a secondary antibody labelled with Alexa fluor 488 (red) while nuclei were labelled with DAPI (blue).
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the double fused CPG2 has enhanced enzyme activity, is 
less immunogenic and more stable than the free CPG2.
In view of these results, we investigated the binding 
of the fusion proteins to cancer cell lines expressing high- 
or low-levels of APN. Our results indicate that the fusion 
proteins bind strongly to cells expressing high levels of 
APN (i. e. the HT1080 cell line). Furthermore, the double 
fusion protein had a significant increase in binding affinity 
compared to the fusion protein with a single copy of the 
CNGRC peptide (Figure 8). Such higher binding affinity is 
expected to provide higher specificity and more restricted 
cytotoxic drug action at tumor sites.
Figure 8: In vitro binding assay of CPG2 and its fusion protein derivatives to cancer cells expressing low (A549) and 
high (HT1080) levels of APN. Binding was measured as described in the Materials & Methods section.
Figure 9: Methotrexate detoxification by CPG2 and its fusion protein derivatives using cells expressing high- or low-
levels of APN. Cancer cell lines expressing low levels of APN (A549, MDA-MB231 and FaDu) or high levels of APN (HT1080, HepG2 
and MDA-MB468) were treated with MTX. Cell viability was then measured as described in the Materials & Methods section. Two groups 
served as negative (non-MTX treated) and positive (treated with MTX only) controls. The results show the percentage of viable cells 
obtained following MTT assay. “student t-test *P < 0.001 relative to the non-treated control”.
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Two in vitro tests of the LDEPT strategy were 
carried out. in the first, we examined the ability of the 
fusion constructs to convert the cytotoxic compound 
methotrexate to a much less toxic product [20]. As 
expected, APN expressing cells that had been pre-
incubated with the proteins showed significantly less 
killing when exposed to methotrexate (Figure 9). In the 
second test we used the prodrug ZD2767P which is one 
of the alkylating mustard prodrugs known to be converted 
by the enzyme CPG2 into a highly cytotoxic drug that 
induces formation of DNA interstrand cross-links. This 
leads to arrest of cell growth (cytostatic effect) with 
induction of apoptosis [31].
We exposed APN expressing cancer cells, pre-treated 
with the fusion proteins or with controls, to the prodrug, 
ZD2767P. The results clearly show that there was a significant 
increase in cell death in the presence of the fusion proteins 
(Figure 10). Importantly, in both tests, the fusion proteins only 
exhibited their effects when the cell lines used expressed high 
levels of APN. Figure 10A shows the effect of the prodrug at 
different concentration. Figure 11 shows the two strategies we 
used to investigate our new conjugates in LDEPT.
Figure 11: The use of a cytotoxic drug and a prodrug to demonstrate two uses of the LDEPT strategy. In (A), accumulation 
of CPG2 on the surface of cancer cells leads to removal of methotrexate (MTX) thereby protecting cells from killing. In principle, this effect 
could be used to remove an excess of MTX. In (B) enzyme-mediated conversion of a prodrug to a cytotoxic compound leads to tumor killing.
Figure 10: Cell killing mediated by CPG2 and its fusion protein derivatives following addition of the prodrug ZD2767P. 
(A) Cancer cell lines, expressing low or high levels of APN, were pre-incubated with CPG2 or its fusion protein derivatives, prior to 
addition of ZD2767P. Cell viability was then measured as described in the Materials & Methods section. “student t-test *P < 0.001 relative 
to the non-treated control”. (B) same as A but at different concentrations of the prodrug.
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MATERIALS AND METHODS
Bacterial strains, vectors, and growth conditions
Escherichia coli (E. coli) DH5α™ (Thermo Fischer 
Scientific) was used as a cloning host, whereas E. coli 
BL21(DE3) RIL (Novagen) was used as an expression 
host. Plasmids pEt28a (Novagen, Stratagene) was used 
for cloning of the single (CNGRC-CPG2) and double 
(CNGRC-CPG2-CNGRC) fusion proteins. These 
bacterial strains were grown in Luria Bertani broth (LB 
Rich Media), which was obtained from Formedium. Agar 
(Formedium) was added to solidify the LB media.
Restriction endonucleases, antibodies and other 
reagents
Restriction enzymes and DNA modifying enzymes 
were obtained from New England Biolabs. Vector 
dephosphorylation was performed using calf intestinal 
alkaline phosphatase (CIAP) that was purchased from 
Thermo Fischer Scientific. GeneJET Plasmid Miniprep and 
GeneJET Gel Extraction kits were obtained from Thermo 
Fischer Scientific, while recombinant proteins were 
purified by affinity chromatography using Ni coated resin 
(Sigma). The DNA and protein markers used (Quick-Load® 
Purple 1 kb DNA Ladder and SeeBlue Plus2 Prestained 
ladder (198-10 kDa) were from NEB and Thermo Fischer 
Scientific, respectively. For immunoblotting, nitrocellulose 
membranes were from Thermo Fischer Scientific while an 
anti-6 His tag antibody mouse 6×-His Tag Monoclonal 
Antibody (HIS. H8) ws obtained from Invitrogen and 
used at 1:2500 dilution as a primary antibody. Rabbit 
polyclonal anti Xen-CPG2 antibody (GE Healthcare) was 
used at 1:3000 dilution while rabbit anti-polyethylene 
glycol antibody [PEG-B-47] (Abcam; ab51257) was 
used at 1:20,000 dilution. The secondary antibodies goat 
anti-mouse IgG H&L (HRP) (ab205719) and goat anti-
Rabbit IgG H&L (HRP) (ab6721) were obtained from 
Abcam and used at 1:4000 and 1:5000, respectively. For 
detection of western blotting, an ECL chemiluminescent 
detection reagent (GE Healthcare) was used as substrate. 
For protein dialysis and buffer exchange, dialysis tubes 
(Spectra/Por 7 Dialysis Tubing, 10 kDa MWCO, 24 mm 
Flat-width, 5 meters/roll (16 ft) obtained from Spectrum 
was used. Immunogenicity assays used the following 
kits in accordance with the manufacturers’ instructions: 
Pierce™ High Capacity Endotoxin Removal Resin 
(Thermo Fisher Scientific); Pierce™ LAL Chromogenic 
Endotoxin Quantitation Kit (Thermo Fisher Scientific) 
and Cell Counting Kit – 8 (Sigma-Aldrich). The cell lines 
used were: MDA-MB468 (human breast adenocarcinoma), 
SW620 (human colorectal adenocarcinoma), MDA-
MB231 (human breast adenocarcinoma), MCF7 (human 
breast adenocarcinoma), A549 (human lung carcinoma), 
HT-1080 (human fibrosarcoma), HepG2 (human 
hepatocellular carcinoma), T47D (human mammary ductal 
carcinoma), LoVo (human colorectal adenocarcinoma), 
HCT (human colorectal carcinoma), H661 (human large 
cell lung cancer), FaDu (human pharyngeal squamous 
cell carcinoma), SCC25 (human tongue squamous cell 
carcinoma). Cell lines were purchased from the American 
Type Culture Collection and cultured in the recommended 
media recommended by the ATCC. ZD2767P was supplied 
by Inovapharm Ltd. as a crystalline product. 1 mg of the 
solid prodrug was dissolved in 1 ml of sterile DMSO to 
make a 2 mM stock solution.
Designing and construction of the single and 
double fusion protein clones
Cloning of the gene encoding a His-tagged version 
of the CPG2 enzyme from Xenophilus azovorans SN213 
has been previously described [32]. The following PCR 
primers were used to prepare DNA fragments encoding 
the single (CNGRC-CPG2) and double (CNGRC-CPG2-
CNGRC) protein constructs:
5′-GGAACCCATATGTGCAACGGTCGTTGTGG 
TGGTGCCCTGGCCCAGAAGCGCGAC-3′ and 5′-AAG 
CTTTCAACCCTTGCCGGCGCCCAGATCCATGATCA 
GGCGGGCCGCCATGTACAGGCGGCG-3′ for the single 
fusion; 5′-GGAACCCATATGTGCAACGGTCGTTGT 
GGTGGTGCCCTGGCCCAGAAGCGCGAC-3′ and 5′-A 
AGCTTTCAACAACGACCGTTGCAACCACCACCCT 
TGCCGGCGCCCAGATCCATGATCAGGCGGGCCG 
C-3′ for the double fusion. The resulting PCR products 
were confirmed by sequencing, cut with restriction 
enzymes HindIII and NdeI, and ligated into the similarly 
digested and dephosphorylated vector pET28a. To 
confirm the structure of the clones, plasmid minipreps 
were prepared and sequenced using the T7 promoter 
and terminator primers, T7F: 5′-TAATACGACTCAC 
TATAGGG-3′ and T7 terminator 5′-GCTAGTTATTGCT 
CAGCGG-3′ (Eurofins).
Expression and purification of fusion proteins
Plasmids encoding CPG2, CNGRC-CPG2 and 
CNGRC-CPG2-CNGRC were transfected into competent 
E. coli BL21 (DE3) RIL cells for protein expression. The 
cells were then grown at 37°C in LB media supplemented 
with kanamycin and chloramphenicol. When the cultures 
reached the required absorbance at 600 nm (0.5–0.6), 
recombinant protein production was induced with IPTG 
before further incubation at 4°C overnight. The following 
day, the cells were collected, resuspended in the lysis 
buffer (20 mM Tris, 100 mM NaCl and PMSF, pH7.4) 
and sonicated to open the cells. The resulting suspension 
was centrifuged, and the soluble protein collected in the 
supernatant. For protein purification, lysates were passed 
through HIS-Select Nickel Affinity Gel for protein capture 
via the His tag associated with the CPG2 protein. After 
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washing and elution with imidazole, the protein was 
dialysed. The purified proteins were separated by SDS-
PAGE and stained with Brilliant Coomassie blue.
Catalytic activity assay of fusion proteins and 
serum stability
The enzymatic activity of the resulting purified 
proteins was determined by measuring the rate of 
methotrexate (MTX) hydrolysis [33]. 590 µl of 0.1 M 
Tris-HCl pH 7.3 containing 0.2 mM ZnSO4 and 5 µl of 
MTX (0.45 mM) was equilibrated at 37°C for 10 minutes 
then the total protein extract of each fusion protein (50 
µg/ml) was added and incubated at 37°C. Samples were 
taken at 10 min intervals, and the decrease in absorbance 
at 320 nm was measured using a Nanodrop 1000 
spectrophotometer (Thermo Fischer Scientific). For the 
kinetics study, the rate of MTX hydrolysis by purified 
proteins (2.12 µg/ml) was determined at different MTX 
concentrations (0.03 up to 0.42 mM) in 0.1 M Tris-HCl 
pH 7.3 and 0.2 mM ZnSO4 using Nunc 96 plates with flat 
bottom wells that were UV transparent. All reactions were 
carried out in triplicate at 37°C for 2 min and the decrease 
in absorbance at 320 nm was determined using Infinite 
M200 PRO NanoQuant Plate Reader (TECAN). Apparent 
Km, Vmax and Kcat values of each protein were determined 
by fitting to the Michaelis-Menten equation using Graph 
pad PRISM 6 software. For serum stability assay, human 
serum was separated from normal blood samples and 
incubated with the purified fusion proteins (0.1 µl/µg) at 
37°C for 14 days. Every 48 hours, a sample was taken and 
tested for CPG2 catalytic activity on MTX.
Circular Dichroism spectroscopy of the 
generated fusion proteins
Circular Dichroism spectroscopy (CD) 
measurements of the single and double fusion proteins 
were performed using a Chirascan spectrometer (Applied 
Photophysics) for 10 µM protein (adjusted using the 
extension coefficient of each protein that were taken as 
ε = 23380 M-1 cm-1 for WT CPG2, 23505 M-1 cm-1 for 
single fusion protein and 23630 for double fusion protein 
measured using a Nanodrop 2000 spectrometer) in 
sterile water. The proteins were examined in a 0.2 mm 
SUPRASIL Quartz demountable rectangular (Hellma®) 
cuvette, with scanning between 180 and 260 nm at 
25°C, band width of 0.5 nm, step size 1 nm and a scan 
time per point of 0.5 s. For each protein scan of repeat 
were averaged and smoothed using Chirascan™ analysis 
software. Water was used as a buffer baseline that was 
measured under the same parameters, then the final spectra 
of each protein were obtained by correcting them for the 
buffer baseline averaged spectra by subtraction.
In addition, secondary structure components of each 
protein were predicted for each corresponding measured 
spectrum by CD spectra deconvolution method using 
CDNN software (version 2.1) in the far UV spectral region 
in the 190–260 nm spectral region. For the deconvolution 
calculations, the number of amino acids of WT CPG2 
was taken as 392 residues, and the molecular weight was 
41,761.48 Da. For the single fusion protein, the number 
of amino acids was taken to be 403 residues and the 
molecular weight was 42,668.53 Da. For the double fusion 
protein, the number of amino acids was taken to be 410 
and the molecular weight was 43,316.25 Da.
Ex-vivo immunogenicity assay
The immunogenicity of the purified fusion 
proteins was determined using human peripheral blood 
mononuclear cells (PBMCs) and in conjunction with a 
proliferation assay. PBMCs from normal donors blood was 
separated and cultured in X-VIVO™ 15 media (1 × 106 
cells/ml in 96 well plate). 10 µl of a purified fusion protein 
was added to achieve a final concentration of 10 µg/ml. 
Prior to adding the fusion proteins, the level of endotoxin 
in the purified fusion protein samples was assessed using a 
Pierce LAL Chromogenic Endotoxin Quantitation Kit and, 
where necessary, high endotoxin levels were reduced using 
Pierce™ High Capacity Endotoxin Removal Resin to ˂ 
0.1EU/ml. Negative controls were without any proteins 
added, while LPS was used as a positive control. PBMCs 
were incubated with the purified fusion proteins for 48 
hrs at 37°C in a CO2 incubator. The T cell proliferation 
assay was performed using a CCK-8 kit, as indicated by 
the manufacturer. 10 µl of CCK-8 working solution was 
added to each well and the plate was incubated at 37°C 
for 4 hours. The resulting absorbance was then read at 450 
nm using an Infinite M200 PRO NanoQuant Plate Reader 
(TECAN).
Measurement of aminopeptidase N levels in 
various cancer cell lines
Cell lines were grown in 96 well plates using their 
recommended media and conditions (MDA-MB231, 
MCF-7, T47D, LoVo H661 A549, FaDu and SCC25 
in RPMI-1640 supplemented with 10% FBS, HepG2, 
HCT and HT1080 in Minimum Essential Medium 
(MEM) supplemented with 10% FBS MDA-MB468 
in Dulbecco’s Modified Eagle’s medium (DMEM) 
supplemented with 10% FBS). The cells were fixed with 
4% paraformaldehyde for 15 minutes, and then blocked 
with 5% BSA in 1× PBS for one hour at room temperature. 
Next, the cells were incubated with mouse anti-CD13 
antibody (WM15 ab7417), followed by washing twice 
with 1× PBS. The cells were then incubated with an anti-
mouse antibody labelled with Alexa Fluor-488 and, before 
scanning, the cell nuclei were stained with DAPI. The 
cells were screened for the level of fluorescence using an 
Array Scan XTI instrument.
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Measurement of in vitro binding of fusion proteins 
to cancer cells differentially expressing APN
HT1080 and A549 cells were seeded at 25,000 
cells/well density in 96 well plates and incubated at 37°C 
overnight. The next day the cells were fixed with 4% 
paraformaldehyde for 15 minutes at room temperature, 
followed by washing with 1 X PBST and blocking 
with 5% bovine serum albumin for 1 hour at room 
temperature. After washing with 1 X PBST three times, 
the cells were incubated with different concentrations 
of the purified fusion proteins (0.063, 0.127, 0.192 and 
0.255 µM), at room temperature for 1 hourThis was 
followed by washing twice with 1 X PBST, addition of 
100 µL (per well) anti-His6-HRP monoclonal antibody 
diluted (1:1000) in 1% BSA and incubation for 1 h at 
room temperature. After that the plate was washed with 
PBST twice, and the chromogenic HRP substrate TMB 
“3,3′,5,5′-Tetramethylbenzidine “ was added (100 µl/well). 
The reaction was stopped by adding 2N H2SO4, and the 
resulting color intensity was measured using an Infinite 
M200 PRO NanoQuant Plate Reader (TECAN) “OD 
at 450 nm”. GraphPad Prism was used to calculate the 
binding affinity and dissociation constants (Kd).
Measurement of in vitro cytotoxicity of MTX and/or 
ZD2767P following treatment with fusion proteins
The cells were dispensed into 96 well plates at 
a density of 20,000 cells/well and allowed to attach 
overnight. The next day, the cells were incubated with 80 
µg/ml of Xen. CPG2c proteins for two hours. The cells 
were washed at least twice with 1× PBS to remove any 
unbound proteins and treated with 5 nM of methotrexate 
(MTX) or different concentration of the prodrug ZD2767P 
(0.1, 0.5 and 1 µM). Several control groups were used 
for each cell line; one was treated only with the fusion 
proteins while others were treated only with MTX or with 
the prodrug.
The cells were grown and treated with fusion 
proteins for 2 hrs, washed and incubated with MTX or 
the prodrug ZD2767P for 1–2 hrs, after that washing and 
incubation of cells in complete media with no proteins 
or drugs for 48 hrs. 10 µl of 5 mg/ml MTT solution was 
added to the cells (final concentration 0.5 mg/ml) and 
incubated for 3–4 hrs. This was followed by washing 
cells with PBS and adding MTT solvent. After 15 min the 
absorbance of resulting color was measured at 570 nm.
Data analysis
Data were processed using GraphPad Prism 5 
software. Statistical analysis was carried with Student’s 
t-test, and results with P < 0.05 or P < 0.001 were defined 
as significant. One-way ANOVA with post hoc Tukey’s test 
were used to compare data of the APN expression level by 
cancer cell lines investigated, differences were considered 
significant when P < 0.001. For the binding affinity assay 
Kd was calculated using nonlinear regression analysis.
CONCLUSIONS
Our work describes two CPG2 fusion proteins for 
the targeted treatment of aminopeptidase N expressing-
cancer cells. Their characteristics suggest that it would 
be beneficial to further investigate their antitumor effects 
in animal models and possibly in clinical studies. Given 
the ease of production of such fusion proteins, their 
lower immunogenicity and the increased enzyme activity 
of the double fusion construct, they have the potential 
to be used in addition to, or replace, antibody-directed 
enzyme prodrug therapy. We name the modified strategy 
as ligand-directed enzyme prodrug therapy (LDEPT).
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